InflaRx N.V (IF0) - Net Assets
Based on the latest financial reports, InflaRx N.V (IF0) has net assets worth €45.37 Million EUR (≈ $53.04 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€65.16 Million ≈ $76.18 Million USD) and total liabilities (€19.79 Million ≈ $23.14 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check IF0 asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €45.37 Million |
| % of Total Assets | 69.63% |
| Annual Growth Rate | N/A |
| 5-Year Change | -21.12% |
| 10-Year Change | N/A |
| Growth Volatility | 28.07 |
InflaRx N.V - Net Assets Trend (2016–2024)
This chart illustrates how InflaRx N.V's net assets have evolved over time, based on quarterly financial data. Also explore InflaRx N.V asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for InflaRx N.V (2016–2024)
The table below shows the annual net assets of InflaRx N.V from 2016 to 2024. For live valuation and market cap data, see IF0 stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €61.42 Million ≈ $71.80 Million |
-40.13% |
| 2023-12-31 | €102.58 Million ≈ $119.93 Million |
+16.11% |
| 2022-12-31 | €88.35 Million ≈ $103.29 Million |
-16.08% |
| 2021-12-31 | €105.28 Million ≈ $123.08 Million |
+35.21% |
| 2020-12-31 | €77.86 Million ≈ $91.03 Million |
-27.33% |
| 2019-12-31 | €107.15 Million ≈ $125.27 Million |
-29.23% |
| 2018-12-31 | €151.39 Million ≈ $176.99 Million |
+26.76% |
| 2017-12-31 | €119.43 Million ≈ $139.63 Million |
+564.90% |
| 2016-12-31 | €-25.69 Million ≈ $-30.03 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to InflaRx N.V's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 30513722100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €393.61 Million | 640.89% |
| Total Equity | €61.42 Million | 100.00% |
InflaRx N.V Competitors by Market Cap
The table below lists competitors of InflaRx N.V ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Deswell Industries Inc
NASDAQ:DSWL
|
$50.36 Million |
|
Metalstech Ltd
AU:MTC
|
$50.36 Million |
|
Heerim Architects & Planners Co. Ltd
KQ:037440
|
$50.39 Million |
|
Guandian Defense Technology Co. Ltd. A
SHG:688287
|
$50.42 Million |
|
Nam Liong Global Corp
TWO:5450
|
$50.33 Million |
|
FingerMotion Inc
NASDAQ:FNGR
|
$50.31 Million |
|
Chin Yang Ind
KO:003780
|
$50.30 Million |
|
TronicS Microsystems SA
PA:ALTRO
|
$50.30 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in InflaRx N.V's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 102,581,731 to 61,416,040, a change of -41,165,691 (-40.1%).
- Net loss of 46,064,402 reduced equity.
- New share issuances of 1,098,289 increased equity.
- Other factors increased equity by 3,800,422.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-46.06 Million | -75.0% |
| Share Issuances | €1.10 Million | +1.79% |
| Other Changes | €3.80 Million | +6.19% |
| Total Change | €- | -40.13% |
Book Value vs Market Value Analysis
This analysis compares InflaRx N.V's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.77x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.36x to 1.77x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €5.02 | €1.83 | x |
| 2018-12-31 | €5.83 | €1.83 | x |
| 2019-12-31 | €4.10 | €1.83 | x |
| 2020-12-31 | €2.76 | €1.83 | x |
| 2021-12-31 | €2.38 | €1.83 | x |
| 2022-12-31 | €1.98 | €1.83 | x |
| 2023-12-31 | €1.74 | €1.83 | x |
| 2024-12-31 | €1.03 | €1.83 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently InflaRx N.V utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -75.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -27784.96%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.24x
- Recent ROE (-75.00%) is below the historical average (-36.29%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | €-6.37 Million |
| 2017 | -20.29% | 0.00% | 0.00x | 1.04x | €-36.18 Million |
| 2018 | -19.69% | 0.00% | 0.00x | 1.05x | €-44.95 Million |
| 2019 | -49.70% | 0.00% | 0.00x | 1.13x | €-63.97 Million |
| 2020 | -43.64% | 0.00% | 0.00x | 1.13x | €-41.77 Million |
| 2021 | -43.34% | 0.00% | 0.00x | 1.19x | €-56.16 Million |
| 2022 | -33.37% | 0.00% | 0.00x | 1.16x | €-38.32 Million |
| 2023 | -41.59% | -67630.69% | 0.00x | 1.17x | €-52.93 Million |
| 2024 | -75.00% | -27784.96% | 0.00x | 1.24x | €-52.21 Million |
Industry Comparison
This section compares InflaRx N.V's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $979,793,893
- Average return on equity (ROE) among peers: -18.73%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| InflaRx N.V (IF0) | €45.37 Million | 0.00% | 0.44x | $50.33 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $5.54 Million | -319.56% | 1.20x | $157.03 Million |
| Theravance Biopharma Inc (0TB) | $441.80 Million | 197.40% | 0.37x | $828.57 Million |
| PreveCeutical Medical Inc (18H) | $-3.60 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $2.53 Billion | -16.11% | 0.12x | $44.01 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $-45.09 Million | 0.00% | 0.00x | $1.12 Billion |
| ZAI LAB LTD0000006 (1ZLB) | $840.90 Million | -30.57% | 0.41x | $2.05 Billion |
| BioNTech SE (22UA) | $1.37 Billion | 1.11% | 0.69x | $23.24 Billion |
| Ascletis Pharma Inc (2VJ) | $2.98 Billion | -7.02% | 0.03x | $2.05 Billion |
| ALPHAMAB ONCOLO.DL-000002 (3NK) | $1.67 Billion | -12.59% | 0.28x | $978.26 Million |
| BIOMIND LABS INC. (3XI) | $-1.43 Million | 0.00% | 0.00x | $3.31 Million |
About InflaRx N.V
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal … Read more